TerminatedPhase 2NCT05788289
A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Principal Investigator
- Anita Kumar, MDMemorial Sloan Kettering Cancer Center
- Intervention
- Tafasitamab(drug)
- Enrollment
- 4 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2024
Study locations (7)
- Memorial Sloan Kettering Basking Ridge (All protocol activities), Basking Ridge, New Jersey, United States
- Memorial Sloan Kettering Monmouth (All protocol activities), Middletown, New Jersey, United States
- Memorial Sloan Kettering Bergen (All protocol activities), Montvale, New Jersey, United States
- Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities), Commack, New York, United States
- Memorial Sloan Kettering Westchester (All protocol activities), Harrison, New York, United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York, New York, United States
- Memorial Sloan Kettering Nassau (All protocol activities), Rockville Centre, New York, United States
Collaborators
Incyte Corporation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05788289 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06675123Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGPHASE2NCT07082686A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)Beijing InnoCare Pharma Tech Co., Ltd.
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT07199296Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentRuijin Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University